& Dean, C
Findings: RCTSTEP-HFpEF DM trial - Semaglutide vs Placebo in Obese Diabetics with HFpEF, NEJM (2024) [PubMed abstract] Design: Randomized, placebo-controlled trial (N=616 | length = 52 weeks) in obese type 2 diabetics (BMI 30) with HFpEF Treatment: Semaglutide titrated to 2.4 mg once weekly vs Placebo Primary outcome: Change from baseline in the Kansas City Cardiomyopathy Questionnaire clinical summary score (KCCQ-CSS
All research involving peptides should be conducted in compliance with applicable local, state, and federal regulations
At Grace + Beauty, we offer a number of highly advanced contouring and sculpting options to help refine your post-weight loss look
The combination of melanocytic stimulation, systemic sympathomimetic activity, and vascular dysregulation associated with melanotan, particularly in the context of unstandardized dosing and formulations and their promotion via social media platforms, highlights the need for stricter regulation and greater public health messaging
Come to Juicy Face and consult with Purnima Balla to find out if Tirzepatide is the right option for your weight loss journey